-
公开(公告)号：US20180057600A1
公开(公告)日：2018-03-01
申请号：US15807351
申请日：2017-11-08
Applicant: Pflzer Inc. , Bristol-Myers Squibb Company
Inventor： Jing MIN , Yanli Wu , Rory F. Finn , Barrett R. Thiele , Wei Liao , Ronald P. Gladue , Arvind Rajpal , Timothy J. Paradis , Peter Brams , Brigitte Devaux , Yi Wu , Kristopher Toy , Heidi N. Leblanc , Haichun Huang
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K2317/14 , C07K2317/21 , C07K2317/565 , C07K2317/92
Abstract: The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.
-
公开(公告)号：US20250129166A1
公开(公告)日：2025-04-24
申请号：US18939765
申请日：2024-11-07
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US11623965B2
公开(公告)日：2023-04-11
申请号：US16103654
申请日：2018-08-14
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Stanley R. Krystek, Jr. , Yong Zhang , Gregory D. Vite , Arvind Rajpal , Chetana Rao-Naik , Paul E. Morin , Mohan Srinivasan , Zheng Lin , Virginie Lafont , Alla Pritsker
Abstract: A prodrugged antibody has a blocking moiety attached to a Cys on its heavy or light chain via a linker having a cleavable moiety. The blocking moiety inhibits binding of the antibody to its antigen. Cleavage of the cleavable moiety releases the blocking moiety and restores ability of the antibody to bind to its antigen.
-
公开(公告)号：US11306150B2
公开(公告)日：2022-04-19
申请号：US16476814
申请日：2018-01-10
Inventor： Robert J. Johnston , Andrew Rankin , Arathi Krishnakumar , Paul O. Sheppard , Arvind Rajpal
Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
公开(公告)号：US20190330364A1
公开(公告)日：2019-10-31
申请号：US16476814
申请日：2018-01-10
Inventor： Robert J. Johnston , Andrew Rankin , Arathi Krishnakumar , Paul O. Sheppard , Arvind Rajpal
IPC: C07K16/28
Abstract: Methods of identifying and using PSGL-1 antagonists are provided. Such methods include, but are not limited to, methods of treating cancer. PSGL-1 antagonists include, but are not limited to, antibodies that bind PSGL-1 and antibodies that bind VISTA, wherein the antibodies inhibit PSGL-1 binding to VISTA, e.g., at acidic pH (e.g., pH 6.0), as well as PSGL-1 and VISTA extracellular domain polypeptides.
-
Patent Agency Ranking
公开(公告)号：US11912776B2
公开(公告)日：2024-02-27
申请号：US17695769
申请日：2022-03-15
Applicant: Pfizer Inc.
Inventor： Tracy Chia-Chien Kuo , Bijan Andre Boldajipour , Javier Fernando Chaparro Riggers , Philippe Duchateau , Roman Galetto , Alexandre Juillerat , Thomas Charles Pertel , Arvind Rajpal , Barbra Johnson Sasu , Cesar Adolfo Sommer , Julien Valton , Thomas John Van Blarcom
IPC: C07K14/705 , C07K16/28 , A61K39/395 , A61K39/00 , C12N5/10 , C07K14/725 , A61K31/7076 , C12N15/63 , A61K35/17 , C12N5/0783 , A61K38/00
CPC classification number: C07K16/2878 , A61K31/7076 , A61K35/17 , A61K39/0011 , A61K39/46 , A61K39/4631 , A61K39/464417 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2896 , C12N5/0636 , C12N5/10 , C12N15/63 , A61K38/00 , A61K2039/505 , A61K2039/5156 , C07K16/2863 , C07K2317/56 , C07K2317/565 , C07K2317/569 , C07K2317/622 , C07K2317/73 , C07K2317/92 , C07K2319/02 , C07K2319/03 , C07K2319/33 , C12N2510/02
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
-
公开(公告)号：US20220340671A1
公开(公告)日：2022-10-27
申请号：US17695769
申请日：2022-03-15
Applicant: Pfizer Inc.
Inventor： Tracy Chia-Chien KUO , Bijan Andre Boldajipour , Javier Fernando Chaparro Riggers , Philippe Duchateau , Roman Galetto , Alexandre Juillerat , Thomas Charles Pertel , Arvind Rajpal , Barbra Johnson Sasu , Cesar Adolfo Sommer , Julien Valton , Thomas John Van Blarcom
IPC: C07K16/28 , C07K14/725 , C07K14/705 , A61K39/00 , A61K31/7076 , C12N15/63 , A61K35/17 , C12N5/10 , C12N5/0783
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
-
公开(公告)号：US11312782B2
公开(公告)日：2022-04-26
申请号：US16384719
申请日：2019-04-15
Applicant: Pfizer Inc.
Inventor： Tracy Chia-Chien Kuo , Bijan Andre Boldajipour , Javier Fernando Chaparro Riggers , Philippe Duchateau , Roman Ariel Galetto , Alexandre Juillerat , Thomas Charles Pertel , Arvind Rajpal , Barbra Johnson Sasu , Cesar Adolfo Sommer , Julien Valton , Thomas John Van Blarcom
IPC: C12N5/10 , C12N15/63 , C07K16/28 , C07K14/705 , C07K19/00 , C07K14/725 , A61K39/00 , A61K31/7076 , A61K35/17 , C12N5/0783 , A61K39/395 , A61K38/00
Abstract: The invention provides CARs (CARs) that specifically bind to BCMA (B-Cell Maturation Antigen). The invention further relates to engineered immune cells comprising such CARs, CAR-encoding nucleic acids, and methods of making such CARs, engineered immune cells, and nucleic acids. The invention further relates to therapeutic methods for use of these CARs and engineered immune cells for the treatment of a condition associated with malignant cells expressing BCMA (e.g., cancer).
-
公开(公告)号：US10793635B2
公开(公告)日：2020-10-06
申请号：US16017974
申请日：2018-06-25
Applicant: PFIZER INC.
Inventor： Tracy Chia-Chien Kuo , Javier Fernando Chaparro Riggers , Wei Chen , Amy Shaw-Ru Chen , Edward Derrick Pascua , Thomas John Van Blarcom , Leila Marie Boustany , Weihsien Ho , Yik Andy Yeung , Pavel Strop , Arvind Rajpal
IPC: A61K39/395 , C07K16/28 , A61K31/454 , A61K31/704 , A61K31/69 , A61K47/68 , A61K39/00
Abstract: The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to BCMA (B-Cell Maturation Antigen) and/or CD3 (Cluster of Differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the BCMA antibodies, compositions comprising the BCMA antibodies, and methods of using the BCMA antibodies and their conjugates for treating conditions associated with cells expressing BCMA (e.g., cancer or autoimmune disease). The invention further relates to heteromultimeric antibodies that specifically bind to CD3 and a tumor cell antigen, (e.g., bispecific antibodies that specifically bind to CD3 and BCMA). Compositions comprising such heteromultimeric antibodies, methods for producing and purifying such heterodimeric antibodies, and their use in diagnostics and therapeutics are also provided.
-
公开(公告)号：US09238691B2
公开(公告)日：2016-01-19
申请号：US14244167
申请日：2014-04-03
Applicant: Pfizer Inc. , Amgen Fremont Inc.
Inventor： Ronald P. Gladue , Bradley T. Keller , Shinji Ogawa , Arvind Rajpal , Laurie A. Tylaska , Shelley Sims Belouski , Larry L. Green , Meina Liang
CPC classification number: C07K16/2866 , A61K2039/505 , C07K2317/53 , C07K2317/56 , C07K2317/76 , C07K2317/92
Abstract: Provided are antibodies including human antibodies and antigen-binding portions thereof that specifically bind to CCR2, preferably human CCR2, and that may inhibit CCR2. The present antibodies may bind to the first and/or second extracellular loops of CCR2. Isolated heavy and light chains derived from the antibodies and nucleic acid molecules encoding the antibodies and chains are provided. Methods of making and using the anti-CCR2 antibodies or antigen-binding portions, and compositions comprising these antibodies or antigen-binding portions, including compositions for diagnosis and treatment, are provided. Also provided are gene therapy methods using nucleic acid molecules encoding the heavy and/or light chains that comprise the human anti-CCR2 antibodies or antigen-binding portions thereof.
Abstract translation: 提供了包括特异性结合CCR2，优选人CCR2的人抗体和其抗原结合部分的抗体，并且可以抑制CCR2。 本抗体可以结合CCR2的第一和/或第二细胞外环。 提供衍生自抗体的分离的重链和轻链以及编码抗体和链的核酸分子。 提供制备和使用抗CCR2抗体或抗原结合部分的方法，以及包含这些抗体或抗原结合部分的组合物，包括用于诊断和治疗的组合物。 还提供了使用编码包含人抗CCR2抗体或其抗原结合部分的重链和/或轻链的核酸分子的基因治疗方法。
-
-
-
-
-
-
-
-
-
Search Results
38
records
(took 0.025 seconds)
